Published

Investigating cue-reactivity as biomarker for treatment success in psilocybin-assisted therapy for alcohol use disorder

An abstract is available from the original source but is not redistributed by this tracker. Read the source record.

Open source BibTeX RIS

Bibliographic context

Journal: Neuroscience Applied
Date: 2022-01-01
Source: OpenAlex
DOI: 10.1016/j.nsa.2022.100102
PubMed: Unavailable

Authors

Nathalie M. Rieser Ladina P Gubser C. Rossgoderer Da Silva Franz X. Vollenweider Marcus Herdener Katrin H. Preller

Watch author

Derived topics and classifications

psilocybin Addiction Biomarkers Other

Citation graph

0 referenced DOIs found in stored source metadata. 1 indexed paper cite this DOI.

Open citation network

Indexed papers citing this DOI

Investigating cue-reactivity as biomarker for treatment success in psilocybin-assisted therapy for alcohol use disorder2022-01-01

Related papers

Pharmacodynamic biomarker - or psychotherapeutic process? Comment on "The role of the psychedelic experience in psilocybin treatment for treatment-resistant depression".Journal of affective disorders · 2026-02-01 Psychedelics: Historical Context, Emerging Science, and Future Clinical FrontiersJournal of Mental Health Disorders · 2026-04-18 Psilocybin-Assisted Psychotherapy for the Treatment of Severe Alcohol Use Disorder: A Double-Blind, Dose-Comparison Concurrent Control Randomized TrialClinicalTrials.gov · 2026-08-13 Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for Alcohol Use DisorderClinicalTrials.gov · 2026-08-12 Insights from the psychedelic experience integration session: Verbatims differentiate 3-month abstinence in alcohol use disorder with depressive symptoms.Journal of affective disorders · 2026-05-01 The QUANTUM Trip Trial - Psilocybin-assisted Therapy for Reducing Alcohol Intake in Patients With Alcohol Use Disorder: A Randomized, Double-blinded, Placebo-controlled Clinical Trial.ClinicalTrials.gov · 2026-03-24 Efficacy in Relapse Prevention: Psilocybin in Alcohol Use Disorder With Depressive SymptomsClinicalTrials.gov · 2026-07-01 Psilocybin Treatment of Major Depressive Disorder With Co-occurring Alcohol Use DisorderClinicalTrials.gov · 2026-03-13